The American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2022 is November 4-9 and attracts clinicians, researchers, scientists, and advocates worldwide. The educational offerings provide attendees the opportunity to learn the latest research, discuss new and emerging treatments for liver diseases, in addition to connecting with leading experts in the hepatology field.
Researchers from Baylor Scott & White sites, including Baylor University Medical Center at Dallas and Baylor Scott & White All Saints Medical Center – Fort Worth will be heavily involved in this year's event with more than 30 scheduled talks and presentations.
A list of Baylor Scott & White presentations can be found below. Additional details about the meeting can be found on the event website.
Baylor Scott & White Presents Research at The Liver Meeting 2022
Featured Presentations and Sessions Highlighting Liver Research
SATURDAY, NOVEMBER 5, 2022
PLENARY SESSION: Liver Transplant Plenary
Assessment of Kidney Function In Patients With Decompensated Cirrhosis: Does Removing Race Variable Improve Performance of New GFR Equations?
-
Speaker: Mohammad Amin Fallahzadeh, MD
-
Time: 9:00 AM-10:30 AM EST
-
Abstract/Study Purpose: Recently, new estimating GFR equations without race were proposed and rapidly implemented across the U.S. (Inker NEJM 2021 CKD-EPI AS). Given the importance of kidney function assessment in cirrhosis/dual organ transplantation, we examined the performance of novel equations as compared to protocol measured GFR (reference standard) in patients listed for liver transplantation. In addition, we compared performance to equation developed in cirrhosis population (Asrani Hepatology 2020/2021 GRAIL).
-
For More Information: Click Here
-
Video Abstract: Click Here
Not All MELD Scores Are Created Equal: MELD Driven By Creatinine Has Lower Intent To Treat Survival Compared To MELD Driven Bilirubin or INR
-
Speaker: Craig Rosenstengle, MD
-
Time: 9:00 AM-10:30 AM EST
-
Abstract/Study Purpose: For the same MELD score at listing, outcomes before and after liver transplantation may vary if the predominant driver of the MELD score is bilirubin, INR or creatinine. For example, a MELD score of 25 driven by creatinine may have different survival as compared to a MELD score of 25 driven by bilirubin. We hypothesized that MELD score subtypes do not have similar intent-to-treat survival.
-
For More Information: Click Here
-
Video Abstract: Click Here
SUNDAY, NOVEMBER 6, 2022
PARALLEL 3 SESSION: Liver Transplantation, Immunosuppression, Outcomes, Complications
Holes In the Safety Net: Most Patients Eligible For The Safety Net Do Not Make It To Kidney After Liver Transplant
-
Speaker: Connor Griffin, MD
-
Time: 9:00 AM-10:30 AM EST
-
Abstract/Study Purpose: The OPTN created strict guidelines on simultaneous liver-kidney transplantation in 2017. This policy provided for a kidney "safety net" so that patients developing kidney failure after liver transplant would be eligible for kidney after liver transplantation (KALT). However, patients meeting eligibility criteria for the safety net may not receive the kidney transplant due to medical complications. UNOS only collects data on those listed for kidney transplantation, potentially excluding patients that are too sick to undergo KALT. Therefore, we examined all safety net eligible patients to determine the fraction that successfully received kidney transplant.
-
For More Information: Click Here
-
Video Abstract: Click Here
POSTER PRESENTATION: Safety and Efficacy of Continuous Infusion Terlipressin in AKI-HRS: The Infuse Study
-
Speaker: Stevan A. Gonzalez, MD
-
Time: 1:00 PM EST
-
Abstract/Study Purpose: Acute Kidney Injury-Hepatorenal syndrome (AKI-HRS), a serious complication of decompensated cirrhosis, has limited therapeutic options and significant mortality. Terlipressin improves renal function in some patients with AKI-HRS. Safety and efficacy of terlipressin may be greater with a continuous infusion strategy as opposed to bolus administration.
-
For More Information: Click Here
-
Video Abstract: Click Here
Chronic Conditions Impact Development of Chronic Kidney Disease and Mortality in patients with cirrhosis – Time to update the International Ascites Club Criteria?
-
Speaker: Rehma Shabbir
-
Time: 1:00 PM- 2:00 PM EST
-
Abstract/Study Purpose: Acute Kidney Injury (AKI) is common in patients with cirrhosis and a major cause of morbidity and mortality. International Club of Ascites (ICA) guidelines are commonly used to define and characterize AKI stages. The ICA guidelines do not account for the presence of chronic conditions such as diabetes, hypertension and obesity. The development of chronic kidney disease after AKI may be driven by the stage of AKI, hepatic decompensation and the presence of chronic conditions.
-
For More Information: Click Here
-
Video Abstract: Click Here
MONDAY, NOVEMBER 7, 2022
ORAL PRESENTATION: Rebound In Serum Creatinine Levels After Terlipressin-Based Treatment Of Patients With Acute Kidney Injur-Hepatorenal Syndrome (HRS-AKI) Is Uncommon Over The Short Term In Patients With A Complete Response: Results From The CONFIRM Study
-
Speaker: Stevan A. Gonzalez, MD
-
Time: 9:00 AM-10:30 AM EST
-
Abstract/Study Purpose: Terlipressin treatment improves renal dysfunction in patients with HRS-AKI. However, there is concern that the reversal of HRS may be transient and that patients may need retreatment. Our analysis investigated the rebound rate of serum creatinine (SCr) levels among patients with HRS-AKI who had responded to terlipressin-based treatment.
-
For More Information: Click Here
-
Video Abstract: Click Here
Practice and Quality Measures in Cirrhosis: What's New in Recent Guidance Documents
-
Speaker: Sumeet K. Asrani, MD, MSc
-
Time: 11:30 AM - 1:00 PM EST
-
For More Session Information: Click Here
Machine Learning Identifies The High Risk Patient With Cirrhosis Using Kidney Trajectory Patterns
-
Speaker: Philipp Schulz, MD
-
Time: 2:00 PM- 3:30 PM EST
-
Abstract/Study Purpose: Progression of kidney dysfunction in patients with decompensated cirrhosis is associated with poor outcomes. However, it is unclear whether certain subsets of patients are at higher risk of progression after development of acute kidney injury (AKI). We aim to determine the prognostic impact of different kidney trajectory patterns in patients with cirrhosis and its relationship between demographic characteristics and comorbidities.
-
For More Information: Click Here
Awards
Early Career Investigator Award in Healthcare Disparities
Dr. Mohammad Amin Fallahzadeh, internal medicine resident at Baylor University Medical Center – Dallas, received an ‘Early Career Investigator Award in Healthcare Disparities Research’ from the AASLD Liver Meeting 2022 for his abstract: Assessment of Kidney Function In Patients With Decompensated Cirrhosis: Does Removing Race Variable Improve Performance of New GFR Equations?
Early Career Investigator Award in Healthcare Disparities
Dr. Craig Rosenstengle, hepatology fellow at Baylor University Medical Center – Dallas, received an ‘Early Career Investigator Award in Healthcare Disparities Research’ from the AASLD Liver Meeting 2022 for his abstract: Not All MELD Scores Are Created Equal: MELD Driven By Creatinine Has Lower Intent To Treat Survival Compared To MELD Driven Bilirubin or INR